A 44-year-old female with paraesthesia and pain on the left anterolateral thigh who had been diagnosed with limb-girdle muscular dystrophy by electromyography and muscle biopsy is presented. Neurological examination revealed atrophy of the proximal muscles of both shoulders, plus pseudo hypertrophy of both calves. Electromyography exhibited a myopathic pattern. Musculoskeletal ultrasound imaging demonstrated a fusiform nerve swelling below the inguinal ligament suggesting lateral femoral cutaneous nerve compression, consistent with meralgia paraesthetica. Treatment with a perineural injection of betamethasone dipropionate and betamethasone sodium phosphate combination, and prilocaine-HCl, under ultrasound guidance, was performed. Symptoms resolved within 6 h. At 3-week follow-up, the patient was asymptomatic, and there was no paraesthesia or pain on examination. In this case, ultrasound-guided perineural injection of the lateral femoral cutaneous nerve with local anaesthetics and steroid served both diagnostic and therapeutic functions.
Introduction
Limb-girdle muscular dystrophy (LGMD) is a heterogeneous group of hereditary, progressive neuromuscular diseases, with primary involvement of the pelvic and shoulder girdle muscles. 1 However, different musculoskeletal symptoms, such as distal muscle weakness, muscle hypertrophy and contracture may be in the clinical picture. 2 Meralgia paraesthetica (MP) is an entrapment neuropathy of lateral femoral cutaneous nerve (LFCN), resulting in numbness and/or paraesthesia in the anterolateral region of the thigh, which is the area of distribution of this nerve. The entrapment syndrome is usually idiopathic but can also be due to trauma/ overuse, leg length discrepancies, prolonged standing and weight gain. 3, 4 Most patients with MP have a favourable course and 85% achieve satisfactory symptom relief from conservative treatment modalities, such as lifestyle modification and the administration of analgesic and anti-inflammatory drugs. Lifestyle modification includes weight loss and the avoidance of tight clothing, such as belts, that may press on the upper thigh/hip area. In severe cases, injection around the nerve (with steroid and local anaesthetic) can be applied. However, a small group of patients experience intractable pain that is refractory to conservative management. In such cases, surgical decompression (neurolysis) or transection of the LFCN has been considered. 5, 6 To our knowledge, no case of entrapment neuropathy associated with LGMD has been reported to date. Here we present a case of MP in a patient who had a 20-year history of LGMD.
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Case A 44-year-old female was admitted to our service complaining of pain, paraesthesia and numbness on the left anterolateral thigh, which had started 6 months earlier.
She had been diagnosed with LGMD 20 years previously by electromyography (EMG) and muscle biopsy. She had difficulty in climbing stairs, rising from a seated position or reaching overhead. Neurological examination revealed atrophy of the proximal muscles involving the deltoid, supraspinatus, triceps brachii and biceps brachii muscles of the both shoulders. There was also pseudo hypertrophy of both calves. Muscle strength testing showed shoulder flexion, extension and adduction muscle strength of 3/5, hip extension and flexion muscle strength of 3/5 (active movement through full range of motion against gravity but without any resistance). Sensory examination revealed pain and a decrease in sensation in the distribution of LFCN. The patient's laboratory testing revealed an elevated creatinine phosphokinase of 1173 U/l (normal range 10-145 U/l). Electrodiagnostic examinations exhibited normal nerve conduction velocity. EMG showed a myopathic pattern similar to previous EMG results.
Musculoskeletal ultrasound imaging demonstrated a fusiform nerve swelling below the inguinal ligament suggesting LFCN compression (Figure 1) . A diagnosis of MP was made. Body mass index value was calculated as 22. There was no history of tight clothing or heavy lifting. The patient was medicated for pain and paraesthesia with analgesics and anti-inflammatory drugs without improvement. Because of the presence of symptoms that affect the daily living activities of the patient, local injection was planned with the expectation of relieving symptoms. Treatment with a perineural injection of 0.5 ml of betamethasone dipropionate (6.43 mg/ml) and betamethasone sodium phosphate (2.63 mg/ml) combination, and 0.5 ml of prilocaine-HCl (20 mg/ml), under ultrasound guidance, was performed. After injection, the patient was bed rested for 30 min and returned home without complications. Symptoms resolved within 6-8 h. At 3-week follow-up, the patient was asymptomatic, and there was no paraesthesia on examination.
Discussion
A central feature of the presentation in this case was pain and paraesthesia, which are not typically predominant symptoms of LGMD. There are various conditions that present similarly to MP, including lumbar radiculopathy, trochanteric bursitis and femoral neuropathy. 7 This case was diagnosed as MP based on clinical grounds, EMG and sonographic findings and lastly, alleviation of pain with injection, which was both diagnostic and therapeutic.
The hip joint, the junction between lower limb and trunk, has a critical role in locomotion. The hip musculature ensures the stabilisation of the trunk throughout the gait cycle. 8 When the hip flexors or extensors are too weak to control the hip joint, compensatory strategies will occur, which can impact gait pattern. Overuse or ''misuse'' was considered to be the reason for the development of MP in this case. US imaging can confirm the target nerve in entrapment neuropathies, and allow injection into the precise location. It has been suggested in the recent literature that US offers an improvement in the diagnosis and treatment of MP, 4,9,10 as we believe occurred in our case. Injection of corticosteroid usually results in short-term pain relief, lasting 4-12 weeks (average 6 weeks) in duration. To assess for recurrence, the patient was instructed to return to the clinic in 3 months.
Although important steps have been taken toward improving treatment of neuromuscular disease during recent decades, no definitive treatments for LGMD exist to date. This report supports the need for careful screening of coincidental musculoskeletal problems such as neuropathy in order to improve the quality of life of patients with LGMD. It also highlights the truism that an underlying pathology is not always the explanation of new symptoms. A case is also made for ultrasound-guided perineural injection of the LFCN with local anaesthetics and steroid serving both a diagnostic and therapeutic role.
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